Matt Sargent

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.

Biotheranostics, Inc. develops and provides diagnostic, prognostic and predictive tests that support physicians in the treatment of cancer patients. It has commercialized two proprietary, highly differentiated products focused on early stage breast cancer and all metastatic cancers, Breast Cancer Index (BCI) and CancerTYPE ID (CTID). The company was founded by Thomas M. Baer in 2008 and is headquartered in San Diego, CA.